TY - JOUR T1 - The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1186/s40425-016-0188-z VL - 4 IS - 1 SP - 90 AU - Michael Boyiadzis AU - Michael R. Bishop AU - Rafat Abonour AU - Kenneth C. Anderson AU - Stephen M. Ansell AU - David Avigan AU - Lisa Barbarotta AU - Austin John Barrett AU - Koen Van Besien AU - P. Leif Bergsagel AU - Ivan Borrello AU - Joshua Brody AU - Jill Brufsky AU - Mitchell Cairo AU - Ajai Chari AU - Adam Cohen AU - Jorge Cortes AU - Stephen J. Forman AU - Jonathan W. Friedberg AU - Ephraim J. Fuchs AU - Steven D. Gore AU - Sundar Jagannath AU - Brad S. Kahl AU - Justin Kline AU - James N. Kochenderfer AU - Larry W. Kwak AU - Ronald Levy AU - Marcos de Lima AU - Mark R. Litzow AU - Anuj Mahindra AU - Jeffrey Miller AU - Nikhil C. Munshi AU - Robert Z. Orlowski AU - John M. Pagel AU - David L. Porter AU - Stephen J. Russell AU - Karl Schwartz AU - Margaret A. Shipp AU - David Siegel AU - Richard M. Stone AU - Martin S. Tallman AU - John M. Timmerman AU - Frits Van Rhee AU - Edmund K. Waller AU - Ann Welsh AU - Michael Werner AU - Peter H. Wiernik AU - Madhav V. Dhodapkar Y1 - 2016/12/01 UR - http://jitc.bmj.com/content/4/1/90.abstract N2 - Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine’s clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.Abbreviations:ADCCAntibody-dependent cell mediated cytotoxicityADCsAntibody-drug conjugatesALLAcute lymphoblastic leukemiaAMLAcute myeloid leukemiaBiTEBispecific T cell engagerBTLAB and T cell lymphocyte attenuatorCALGBCancer and leukemia group BCARChimeric antigen receptorCDCComplement-dependent cytotoxicityCHOPCyclophosphamide, adriamycin, vincristine, prednisoneCHVPCyclophosphamide, doxorubicin, and teniposideCIRCumulative incidence of relapseCLLChronic lymphocytic leukemiaCRComplete responseCRSCytokine release syndromeCTLCytotoxic T lymphocyteCTLA-4Cytotoxic lymphocyte antigen-4CVPCyclophosphamide, vincristine, and prednisoneCyBorDCyclophosphamide, bortezomib, and dexamethasoneDCDendritic cellDLBCLDiffuse large B cell lymphomaEBVEpstein-barr virusEFSEvent-free survivalElo-RdElotuzumab with lenalidomide plus dexamethasoneFDAFood and drug administrationGCBGerminal center b cell-likeHLHodgkin lymphomaHSCTHematopoietic stem cell transplantationICInvestigator’s choiceIFNInterferonIgImmunoglobulinILInterleukinIL-2RɑInterleukin-2 receptor ɑIMiDsImmune-modulating drugsJAKJanus kinaseKRdCarfilzomib with lenalidomide plus dexamethasoneLAG-3Lymphocyte activation gene-3LRLenalidomide plus rituximabmAbsMonoclonal antibodiesMCLMantle cell lymphomaMGUSMonoclonal gammopathy of undetermined significanceMIL/TILMarrow and tumor-infiltrating lymphocytesMMMultiple myelomaMPTMelphalan, prednisolone, and thalidomideMRDMinimal residual diseasenCRNear complete responseNHLNon-hodgkin lymphomaNKNatural killerORRObjective response rateOSOverall survivalPD-1Programmed cell death-1PFSProgression-free survivalRdLenalidomide plus dexamethasoneRRMMRelapsed/refractory multiple myelomaSITCSociety for immunotherapy of cancerSTINGStimulator of interferon genesSWOGSouthwestern oncology groupTCRT cell receptorTIM-3T cell immunoglobulin mucin-3VRdBortezomib with lenalidomide plus dexamethasoneXBP-1X-box binding protein 1 ER -